Cita APA

Palafox, M., Gonzalez-Perez, A., Arribas, J., López Bigas, N., & Serra, V. (2022). High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.

Citación estilo Chicago

Palafox, Marta, Abel Gonzalez-Perez, Joaquín Arribas, Núria López Bigas, y Violeta Serra. High P16 Expression and Heterozygous RB1 Loss Are Biomarkers for CDK4/6 Inhibitor Resistance in ER+ Breast Cancer. 2022.

Cita MLA

Palafox, Marta, et al. High P16 Expression and Heterozygous RB1 Loss Are Biomarkers for CDK4/6 Inhibitor Resistance in ER+ Breast Cancer. 2022.